Alnylam Pharmaceuticals (ALNY) Cash & Current Investments (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has reported Cash & Current Investments for 18 consecutive years, with $3.3 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Current Investments rose 15.77% year-over-year to $3.3 billion; the trailing twelve-month figure through Jun 2026 stood at $3.3 billion (up 15.77% YoY), and the FY2025 full-year result was $2.9 billion, up 8.18% from the prior year.
• Cash & Current Investments rose to $3.3 billion in Q2 2026 per ALNY's latest filing, from $3.0 billion in the prior quarter.
• Across five years, Cash & Current Investments topped out at $3.3 billion in Q2 2026 and bottomed at $2.0 billion in Q2 2023.
• Historically, Cash & Current Investments has averaged $2.5 billion across 5 years, with a median of $2.5 billion in 2023.
• The widest YoY moves for Cash & Current Investments: up 33.58% in 2022, down 8.62% in 2022.
• Over 5 years, Cash & Current Investments stood at $2.2 billion in 2022, then advanced by 12.08% to $2.4 billion in 2023, then rose by 10.72% to $2.7 billion in 2024, then gained by 8.18% to $2.9 billion in 2025, then rose by 13.74% to $3.3 billion in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $3.3 billion, $3.0 billion, and $2.9 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.